• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23369 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk. Update 2018
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Patisiran (hereditary transthyretin amyloidosis with polyneuropathy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     National Institute for Health and Care Excellence (NICE) Dupilumab for treating moderate to severe atopic dermatitis. NICE technology appraisal guidance 534
2018     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Support for unaccompanied children and youth – effects, experiences and perceptions]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Metreleptin (lipodystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     National Institute for Health and Care Excellence (NICE) Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine. NICE technology appraisal guidance 535
2018     NIHR Health Technology Assessment programme Improving the Quality of Dentistry (IQuaD): A cluster factorial randomised controlled trial comparing the effectiveness and cost-benefit of oral hygiene advice and/or periodontal instrumentation with routine care for the prevention and management of periodontal disease in dentate adults attending dental primary care
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sitagliptin (type 2 diabetes mellitus) - Benefit assessment according to § 35a Social Code Book V (expiry of the decision)]
2018     Agency for Healthcare Research and Quality (AHRQ) Breastfeeding programs and policies, breastfeeding uptake, and maternal health outcomes in developed countries
2018     National Institute for Health and Care Excellence (NICE) Alectinib for untreated ALK-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 536
2018     National Institute for Health and Care Excellence (NICE) Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 537
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inotersen (hereditary transthyretin amyloidosis with polyneuropathy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     National Institute for Health and Care Excellence (NICE) Dinutuximab beta for treating neuroblastoma. NICE technology appraisal guidance 538
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib (melanoma) - Benefit assessment according to §35a Social Code Book V]
2018     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma. NICE technology appraisal guidance 540
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trametinib (melanoma) - Benefit assessment according to §35a Social Code Book V]
2018     The Regional Health Technology Assessment Centre (HTA-centrum) Effects of lung volume reduction with endobronchial valves in patients with severe chronic obstructive pulmonary disease. Updated report
2018     National Institute for Health and Care Excellence (NICE) Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia. NICE technology appraisal guidance 541
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2018     The Regional Health Technology Assessment Centre (HTA-centrum) Gender affirmation surgery for gender dysphoria - effects and risks
2018     National Institute for Health and Care Excellence (NICE) Cabozantinib for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 542
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vestronidase alfa (mucopolysaccharidosis type VII) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     The Regional Health Technology Assessment Centre (HTA-centrum) Effects of passive movement therapy in patients with stroke, spinal cord injury, or need of intensive care
2018     National Institute for Health and Care Excellence (NICE) Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 543
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Liposomal combination of cytarabine and daunorubicin (acute myeloid leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     National Institute for Health and Care Excellence (NICE) Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma. NICE technology appraisal guidance 544
2018     Agency for Care Effectiveness (ACE) 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET-CT) for oncological indications
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Palbociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2018     National Institute for Health and Care Excellence (NICE) Gemtuzumab ozogamicin for untreated acute myeloid leukaemia. NICE technology appraisal guidance 545
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Caplacizumab (acquired thrombotic thrombocytopenic purpura) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     National Institute for Health and Care Excellence (NICE) Padeliporfin for untreated localised prostate cancer. NICE technology appraisal guidance 546
2018     Haute Autorite de sante (HAS) [Autism spectrum disorder: Warning signs, detection, diagnosis and assessment in children and adolescents]
2018     NIHR Health Technology Assessment programme Standing frames as part of postural management for children with spasticity. What is the acceptability of a trial to determine the efficacy of standing frames?
2018     NIHR Health Technology Assessment programme Combined feasibility and external pilot study to inform the design and conduct of the Fluids in Shock (FiSh) trial
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mepolizumab (asthma) - Benefit assessment according to §35a Social Code Book V]
2018     Agency for Healthcare Research and Quality (AHRQ) Drug therapy for early rheumatoid arthritis: a systematic review update
2018     National Institute for Health and Care Excellence (NICE) Tofacitinib for moderately to severely active ulcerative colitis. NICE technology appraisal guidance 547
2018     National Institute for Health and Care Excellence (NICE) Neuropad for detecting preclinical diabetic peripheral neuropathy. NICE medical technologies guidance 38
2018     NIHR Health Technology Assessment programme Gastrostomy versus nasogastric tube feeding for chemoradiation patients with head and neck cancer: the TUBE pilot RCT
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Support for the development of an S3 guideline on natural childbirth - Evidence reports]
2018     National Institute for Health and Care Excellence (NICE) Decitabine for untreated acute myeloid leukaemia (terminated appraisal). NICE technology appraisal guidance 548
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Support for the development of an S3 guideline on natural childbirth - Evidence reports]
2018     Agency for Healthcare Research and Quality (AHRQ) Effectiveness of indoor allergen reduction in management of asthma
2018     National Institute for Health and Care Excellence (NICE) Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal). NICE technology appraisal guidance 549
2018     National Institute for Health and Care Excellence (NICE) iFuse for treating chronic sacroiliac joint pain. NICE medical technologies guidance 39
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tenofovir alafenamide (chronic hepatits B) - Benefit assessment according to §35a Social Code Book V]
2018     National Institute for Health and Care Excellence (NICE) Vandetanib for treating medullary thyroid cancer. NICE technology appraisal guidance 550
2018     NIHR Health Technology Assessment programme Negative-pressure wound therapy versus standard dressings for adults with an open lower limb fracture: the WOLLF RCT
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Encorafenib (melanoma) - Benefit assessment according to §35a Social Code Book V]
2018     National Institute for Health and Care Excellence (NICE) Lenvatinib for untreated advanced hepatocellular carcinoma. NICE technology appraisal guidance 551
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Binimetinib (melanoma) - Benefit assessment according to §35a Social Code Book V]
2018     National Institute for Health and Care Excellence (NICE) Liposomal cytarabine-daunorubicin for untreated acute myeloid leukaemia. NICE technology appraisal guidance 552
2018     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. NICE technology appraisal guidance 554
2018     National Institute for Health and Care Excellence (NICE) Peristeen Plus transanal irrigation system for managing bowel dysfunction. NICE medical technologies guidance 36
2018     NIHR Health Technology Assessment programme Aerobic and strength training exercise programme for cognitive impairment in people with mild to moderate dementia: the DAPA RCT
2018     National Institute for Health and Care Excellence (NICE) Thopaz+ portable digital system for managing chest drains. NICE medical technologies guidance 37
2018     Agency for Healthcare Research and Quality (AHRQ) Intermittent inhaled corticosteroids and long-acting muscarinic antagonists for asthma
2018     NIHR Health Technology Assessment programme A randomised controlled trial and economic evaluation of intraoperative cell salvage during caesarean section in women at risk of haemorrhage: the SALVO (cell SALVage in Obstetrics) trial
2018     NIHR Health Technology Assessment programme Nicotine preloading for smoking cessation: the Preloading RCT
2018     Health Quality Ontario (HQO) Bilateral Cochlear Implantation: A Health Technology Assessment
2018     NIHR Health Technology Assessment programme Closing five Emergency Departments in England between 2009 and 2011: the closED controlled interrupted time-series analysis
2018     Penn Medicine Center for Evidence-based Practice (CEP) Palliative care in the outpatient setting for patients with heart failure or advanced lung disease
2018     NIHR Health Technology Assessment programme AVURT: aspirin versus placebo for the treatment of venous leg ulcers a Phase II pilot randomised controlled trial
2018     Penn Medicine Center for Evidence-based Practice (CEP) Management structures for hospital nursing
2018     Agency for Healthcare Research and Quality (AHRQ) Lower limb prostheses: measurement instruments, comparison of component effects by subgroups, and long-term outcomes
2018     Penn Medicine Center for Evidence-based Practice (CEP) Treatment of severe acute medical-psychiatric comorbidity in hospitalized patients
2018     NIHR Health Technology Assessment programme Chondroitin sulphate for hand osteoarthritis: a randomised, placebo-controlled trial in primary care: the FACTUAL STUDY
2018     Penn Medicine Center for Evidence-based Practice (CEP) Diagnosis and treatment of gastrointestinal bleeding in patients with left ventricular assist devices
2018     NIHR Health Technology Assessment programme Long-term weight loss following a randomised controlled trial of a weight management programme for men delivered through professional football clubs: the Football Fans in Training follow-up study
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Femoral neck fracture: evaluation of the hospital care process]
2018     NIHR Health Technology Assessment programme Enteral lactoferrin to prevent infection for very preterm infants: the ELFIN RCT
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy and safety of bariatric surgery in individuals with morbid obesity]
2018     Penn Medicine Center for Evidence-based Practice (CEP) Cognitive therapy for schizophrenia
2018     Andalusian Health Technology Assessment Area (AETSA) Electrical stimulation of peripheral nerves for treating chronic refractory pain
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy, safety, and usefulness of genistein in patients with Sanfilippo syndrome]
2018     NIHR Health Technology Assessment programme Understanding variation in ambulance service non-conveyance rates: a mixed methods study
2018     Penn Medicine Center for Evidence-based Practice (CEP) Nurse-directed discontinuation of continuous ECG monitoring among non-ICY inpatients
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Analysis of diagnostic performance of transbronchial lung biopsy using cryoprobe (cryobiopsy) in the study of diffuse lung diseases]
2018     NIHR Health Technology Assessment programme Intramedullary nail fixation versus locking plate fixation for adults with a fracture of the distal tibia: the UK FixDT RCT
2018     NIHR Health Technology Assessment programme The feasibility of early pulmonary rehabilitation and activity after COPD exacerbations: external pilot randomised controlled trial, qualitative case study and exploratory economic evaluation
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Enzyme replacement therapy in lysosomal storage diseases: systematic review and budgetary impact. Update]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Proton therapy in cancer treatment. Update]
2018     Agency for Care Effectiveness (ACE) Ivabradine for the treatment of chronic stable angina and chronic heart failure
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Shoulder arthroscopy: appropriate use]
2018     Agency for Care Effectiveness (ACE) Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Effectiveness and cost-effectiveness of bilateral cochlear implants in children and adults]
2018     Andalusian Health Technology Assessment Area (AETSA) [Digital tomosynthesis in breast cancer: meta-analysis]
2018     Agency for Care Effectiveness (ACE) LAMA & LAMA/LABA for chronic obstructive pulmonary disease (COPD)
2018     Andalusian Health Technology Assessment Area (AETSA) Bibliographic review on the diagnosis, treatment and follow-up of Kawasaki disease
2018     Agency for Healthcare Research and Quality (AHRQ) Mobile applications for self-management of diabetes
2018     Andalusian Health Technology Assessment Area (AETSA) 18F-FDG PET in early diagnosis of degenerative diseases of the central nervous system
2018     Agency for Care Effectiveness (ACE) Solifenacin for treating overactive bladder
2018     Andalusian Health Technology Assessment Area (AETSA) Prognostic genomic tests in early breast cancer: up-date of evidence.
2018     NIHR Health Technology Assessment programme Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT
2018     Agency for Care Effectiveness (ACE) Second-generation antipsychotic injections for treating schizophrenia
2018     Andalusian Health Technology Assessment Area (AETSA) Alectinib as monotherapy for the first-line treatment of adult patients with ALK positive advanced non-small cell lung cancer. EUnetHTA adopted HTA report
2018     Agency for Care Effectiveness (ACE) Lanthanum carbonate and sevelamer carbonate for treating hyperphosphataemia in patients with chronic kidney disease
2018     Agency for Healthcare Research and Quality (AHRQ) Noninvasive nonpharmacological treatment for chronic pain: a systematic review
2018     NIHR Health Technology Assessment programme Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT
2018     Andalusian Health Technology Assessment Area (AETSA) Midostaurin with standard chemotherapy in FLT3-positive acute myeloid leukaemia. EUnetHTA adopted HTA report.